Plant ID: NPO15151
Plant Latin Name: Syringa vulgaris
Taxonomy Genus: Syringa
Taxonomy Family: Oleaceae
NCBI TaxonomyDB:
34270
Plant-of-the-World-Online:
n.a.
Antiperiodic; Febrifuge; Mouthwash; Tonic; Vermifuge
India; China; Russia
NPSR1; | |
MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
CA12; CA7; | |
TYR; | |
ALOX12; HSD17B2; HSD17B10; NOX4; POLB; | |
KDM4E; | |
AHR; | |
FUT7; | |
LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.011E-07 | 4.865E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.639E-07 | 5.224E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 6.778E-07 | 8.682E-04 | ALOX12, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.209E-06 | 2.040E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 2.874E-06 | 2.167E-03 | AXL, FLT3, IGF1R, KDR, MET |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.936E-06 | 2.167E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.936E-06 | 2.167E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 3.714E-06 | 2.384E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 5.668E-06 | 3.048E-03 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, LMNA, PIM1 |
BP | GO:0032502; developmental process | GO:0007568; aging | 8.270E-06 | 3.832E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.864E-06 | 4.021E-03 | CYP1A1, CYP1A2 |
BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 1.210E-05 | 5.001E-03 | AHR, ALOX12, CDK1, CYP1B1, FLT3, IGF1R, KDR, LMNA, NOX4, PIM1 |
MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 1.496E-05 | 5.816E-03 | CYP1A1, CYP1A2, KDM4E |
BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 1.691E-05 | 6.437E-03 | AXL, CDK1, CYP1A1, CYP1A2, CYP1B1, KDR |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.764E-05 | 6.510E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.054E-05 | 7.453E-03 | CDK1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4, TYR |
BP | GO:0065007; biological regulation | GO:0042592; homeostatic process | 2.103E-05 | 7.507E-03 | ALOX12, AXL, CA12, CA7, FLT3, MET, NOX4, NPSR1, POLB |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.539E-07 | 2.138E-05 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.478E-07 | 2.138E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.457E-05 | 3.205E-04 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.936E-05 | 1.474E-03 | CYP1A2, CYP1A1, CYP1B1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.682E-04 | 4.414E-03 | FUT7, HSD17B2, CYP1A2, CYP1A1, ALOX12, TYR, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.263E-04 | 1.668E-03 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.856E-04 | 2.042E-03 | CA12, CA7 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
NA: NA | HIV infections | NA | AHR; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |